Portal de Periódicos da CAPES

High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

2024; American Medical Association; Volume: 81; Issue: 5 Linguagem: Inglês

10.1001/jamaneurol.2024.0395

2168-6157

Guillaume Jouvenot, Guilhem Courbon, Mathilde Lefort, Fabien Rollot, Romain Casey, Emmanuelle Le Page, Laure Michel, Gilles Edan, de Sèze, Laurent Kremer, Kévin Bigaut, Sandra Vukusic, Guillaume Mathey, Jonathan Ciron, Aurélie Ruet, Élisabeth Maillart, Pierre Labauge, Hélène Zéphir, Caroline Papeix, Gilles Defer, Christine Lebrun‐Frénay, Thibault Moreau, David Laplaud, Ėric Berger, Bruno Stankoff, Pierre Clavelou, Éric Thouvenot, Olivier Heinzlef, Jean Pelletier, Alkhedr Abdullatif, Olivier Casez, Bertrand Bourre, Philippe Cabre, Abir Wahab, Laurent Magy, Jean‐Philippe Camdessanché, Inès Doghri, Solène Moulin, Haifa Ben-Nasr, Céline Labeyrie, Karolina Hankiewicz, Jean‐Philippe Neau, Corinne Pottier, Chantal Nifle, Nicolas Collongues, Anne Kerbrat, François Cotton, Pascal Douek, Francis Guillememin, Alexandre Pachot, Javier Olaiz, Claire Rigaud-Bully, Romain Marignier, Marc Debouverie, Catherine Lubetzki, Mikaël Cohen, Agnès Fromont, Sandrine Wiertlewsky, Bertrand Audoin, C. Giannesini, Olivier Gout, Alexis Montcuquet, Serge Bakchine, Aude Maurousset, Nicolas Maubeuge,

Systemic Sclerosis and Related Diseases

A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity.